Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lafora disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Lafora disease. Displaying page 1 of 1.
    EudraCT Number: 2023-000185-34 Sponsor Protocol Number: VAL1221-ITLAFORA-01 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA USL DI BOLOGNA
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF VAL-1221 ON SUBJECTS WITH LAFORA DISEASE
    Medical condition: patients with mid- to late stage Lafora Desease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002147-15 Sponsor Protocol Number: 200200 Start Date*: Information not available in EudraCT
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DI MANTOVA
    Full Title: Intravenous immunoglobulin for Unverricht–Lundborg disease: single-patient trial.
    Medical condition: Unverricht-Lundborg disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10054858 Unverricht's syndrome LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10054895 Baltic myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054894 Unverricht-Lundborg disease LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003210-33 Sponsor Protocol Number: ERPME01 Start Date*: 2007-08-03
    Sponsor Name:Department of Neurology, Turku University Hospital
    Full Title: Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type
    Medical condition: Progressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054895 Baltic myoclonic epilepsy PT
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001536-46 Sponsor Protocol Number: N01236 Start Date*: 2006-11-14
    Sponsor Name:UCB S.A.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult pat...
    Medical condition: Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054894 Unverricht-Lundborg disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-000169-12 Sponsor Protocol Number: N01187 Start Date*: 2006-09-28
    Sponsor Name:UCB S.A.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult pat...
    Medical condition: Patients with genetically ascertained Unverricht-Lundborg disease (ULD).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054894 Unverricht-Lundborg disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) FR (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 16:05:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA